Consistently, inhibiting DGAT2 activity by a DGAT2 inhibitor (PF-06424439) effectively reduced the content of LDs and cell invasion ability in breast cancer MCF-7 cells, increased expression of E-cadherin, and suppressed expression of Vimentin and Snail [123]. Here, DGAT2 is linked to breast cancer.